• Space travel risks: How does the immune system react to zero gravity?

    More than in any previous year, 2023 has seen a rising number of "space tourists". Besides the effects of zero gravitiy, does space impact our immune system?

  • 5 abstracts awarded at UEG WEEK 2023

    The annual international congress took place as a hybrid event in Copenhaguen and online during 14-16 October with over 11,000 participants.

  • Novel drugs for allergy treatment

    Various chronic allergic diseases still need treatment options. Novel agents are under investigation or were approved, diversifying options and increasing efficacy.

  • The topical armamentarium for AD is growing

    With many studies on novel compounds underway, more options for topical treatments of atopic dermatitis (AD) will soon be within reach.

  • Onychomycosis: where do we stand?

    Oral onychomycosis treatment is still the gold standard, but topical armamentarium use is rising, although use of many novel oral and topical agents is off-label.

  • Remibrutinib reduces itch, sleep, and activity impairment in patients with CSU

    In 6 dosage types of remibrutinib, chronic spontaneous urticaria patients benefitted in symptoms such as itch, sleep, and activity, already after 2 weeks.

  • Generalised pustular psoriasis: IL-36 inhibits new flares up to week 48

    IL-36 receptor antibody spesolimab improved erythema, pustulation, and scaling/crusting of skin lesions in generalised pustular psoriasis (GPP).

  • Innovative wound gel significantly reduces daily dressing changes in epidermolysis bullosa

    A post-hoc analysis of the EASE trial revealed that birch extract gel significantly lowered changes, and alleviated the burden of this disease.

  • Differential effect of biologics for psoriasis on the risk of developing arthritis

    A study including 7,144 patients revealed that therapy with IL-23 blockers was associated with lower risk of inflammatory or psoriasis arthritis.

  • Dr Pedro Mendes Bastos on AD differences between children and adults

    Dr Mendes Bastos addressed the heterogeneity of atopic dermatitis patients, causes, and therapy options, and the ongoing research to address them.

  • Promising results in AD treatment with an OX40 ligand inhibitor

    Clinically meaningful improvements in Eczema Area and Severity Index (EASI) were observed with amlitelimab treatment for atopic dermatitis.

  • Alopecia areata: Ritlecitinib generates substantial re-growth of scalp hair

    Excluding severe AA, 83–93% of participants in the ALLEGRO-LT trial reached an 80% re-growth of scalp hair or more after 15 months of treatment.

  • Skin tape stripping: Can it pave the way for early diagnosis in HS?

    Skin tape stripping is an effective, non-invasive way to detect biomarkers associated with early disease in hidradenitis suppurativa.

  • IL-23p19 inhibitors have a superior drug survival compared with other biologics

    A cohort study from the BADBIR registry revealed that IL-23p19 inhibitors are associated with the highest drug survival regarding effectiveness and safety.

  • Dupilumab: a future option for severe hand eczema?

    In a small study, treating different severe hand eczemas with dupilumab led to favourable results. At week 16, 19 of 20 participants reached HECSI75.

  • Vitiligo: Oral JAK1 inhibitor induces increasing repigmentation over time

    Continuing povorcitinib treatment after a 6-month double-blind phase led to additional repigmentation for many participants of a vitiligo phase 2b trial.

  • Women with psoriasis face increased adverse effects with systemic therapy

    Long-term conventional systemic therapies lead to higher drug-related adverse events and treatment discontinuation rates compared with biologics.

  • Patience is rewarded in initial non-responders to topical ruxolitinib with vitiligo

    Extended treatment with ruxolitinib cream resulted in substantial response rates in patients who had demonstrated no or little response after 6 months.

  • Nanobody sonelokimab shows efficacy in hidradenitis suppurativa

    The agent led to remarkable clinical responses for hidradenitis suppurative in the phase 2 MIRA trial. It was relatively well tolerated without new safety signals.

  • JAK inhibitor provides sustained skin clearance in adolescents and adults with AD

    Upadacitinib therapy led to robust clinical efficacy and itch relief in adolescents and adults with moderate-to-severe atopic dermatitis in 3 ongoing phase 3 trials.

  • 9 |
  • 10 |
  • 11 |
  • 12 |
  • 13 |
  • 14 |
  • 15 |
  • 16 |
  • 17 |
  • 18 |
  • 19 |